Nicole Mc Carthy

Breast Canc Trials

关注

立即认领

关注

立即认领

基本信息

浏览量：5

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 7 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

时间

引用量

主题

期刊级别

合作者

合作机构

Palbociclib Combined with Endocrine Treatment in Hormone Receptor-Positive, HER2-negative Breast Cancer Patients with High Relapse Risk after Neoadjuvant Chemotherapy: Subgroup Analyses of Premenopausal Patients in PENELOPE-B

F. Marme,M. Martin,M. Untch,C. Thode,H. Bonnefoi,S. b. Kim,H. Bear,N. Mc Carthy,K. Gelmon,J. A. Garcia-Saenz,C. M. Kelly,T. Reimer, O. Valota,M. Toi,H. S. Rugo,M. Gnant,A. Makris, M. Bassy, Z. Zhang,J. Furlanetto,V. Nekljudova,S. Loibl

ESMO Open（2024）

引用2浏览0WOS引用

Patient-reported Outcomes in High-Risk HR+ /HER2- Early Breast Cancer Patients Treated with Endocrine Therapy with or Without Palbociclib Within the Randomized PENELOPEB Study

Jose Angel Garcia-Saenz,Frederik Marme,Michael Untch,Herve Bonnefoi,Sung-Bae Kim,Harry Bear,Nicole Mc Carthy,Karen Gelmon,Miguel Martin,Catherine M. Kelly,Toralf Reimer,Masakazu Toi,Ernest Law,Helen Bhattacharyya,Michael Gnant,Andreas Makris,Sabine Seiler,Nicole Burchardi,Valentina Nekljudova,Sibylle Loibl,Hope S. Rugo

EUROPEAN JOURNAL OF CANCER (2024)

引用0浏览0WOS引用

Detection of Circulating Tumor DNA Following Neoadjuvant Chemotherapy and Surgery to Anticipate Early Relapse in ER Positive and HER2 Negative Breast Cancer: Analysis from the PENELOPE-B Trial

Nicholas C. Turner,Frederik Marme,Sung-Bae Kim,Herve R. Bonnefoi,Jose Garcia-Saenz, Antonio A. Torres,Harry Douglas Bear,Hans Tesch,Mireia Mele Olive,Nicole Mc Carthy,Josefina Cruz Jurado,Seock-Ah Im,Yuan Liu,Zhe Zhang,Karsten Ernst Weber,Barbel Felder,Valentina Nekljudova,Toralf Reimer,Carsten Denkert,Sibylle Loibl

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023)

引用1浏览0引用

Subgroup of Post-Neoadjuvant Luminal-B Tumors Assessed by HTG in PENELOPE-B Investigating Palbociclib in High Risk HER2-/HR+ Breast Cancer with Residual Disease

Carsten Denkert,Frederik Marme,Miguel Martin,Michael Untch,Herve R. Bonnefoi,Agnieszka Katarzyna Witkiewicz,Seock-Ah Im,Angela DeMichele,Laura Van 't Veer,Nicole Mc Carthy,Karen A. Gelmon,Nicholas C. Turner,Federico Rojo,Peter A. Fasching,Julia Teply-Szymanski,Yuan Liu,Masakazu Toi,Michael Gnant,Karsten Ernst Weber,Sibylle Loibl

Journal of Clinical Oncology（2021）

引用3浏览0引用

Phase III Study of Palbociclib Combined With Endocrine Therapy in Patients With Hormone Receptor-Positive, HER2-Negative Primary Breast Cancer and With High Relapse Risk After Neoadjuvant Chemotherapy: First Results From PENELOPE-B

Sibylle Loibl,Frederik Marme,Miguel Martin,Michael Untch,Herve Bonnefoi,Sung-Bae Kim,Harry Bear,Nicole Mc Carthy,Mireia Mele Olive,Karen Gelmon,Jose Garcia Saenz,Catherine M. Kelly,Toralf Reimer,Masakazu Toi,Hope S. Rugo,Sabine Seiler,Valentina Nekljudova,Carsten Denkert,Michael Gnant,Andreas Makris,Nicole Burchardi,Gunter von Minckwitz

CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY（2021）

引用0浏览0引用

Abstract GS1-02: Phase III Study of Palbociclib Combined with Endocrine Therapy (ET) in Patients with Hormone-Receptor-positive (HR+), HER2-negative Primary Breast Cancerand with High Relapse Risk after Neoadjuvant Chemotherapy (NACT): First Results from PENELOPE-B

Sibylle Loibl,Frederik Marmé,Miguel Martin,Michael Untch,Hervé Bonnefoi,Sung-Bae Kim,Harry Bear,Nicole Mc Carthy,Mireia Melé Olivé,Karen Gelmon,José García Sáenz,Catherine M Kelly,Toralf Reimer,Masakazu Toi,Hope S Rugo,Sabine Seiler,Valentina Nekljudova,Carsten Denkert,Michael Gnant,Andreas Makris,Nicole Burchardi,Gunter von Minckwitz

Cancer Research（2021）

引用27浏览0引用

Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancerand with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENELOPE-B

CANCER RESEARCH（2021）

引用9浏览0引用

作者统计

#Papers: 7

#Citation: 42

H-Index: 3

G-Index: 5

Sociability: 4

Diversity: 2

Activity: 11

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn